Reversibility of dopamine receptor antagonist-induced hyperprolactinemia and associated histological changes in Tg RasH2 wild-type mice.
The purpose of this study was to better understand the biological effects of increased prolactin levels induced in mice by dopamine D2 receptor antagonist molindone treatment. Toxicokinetics, prolactin levels, and reproductive tissue histology were evaluated in Tg rasH2 wild-type mice treated orally with molindone at 0, 5, 15, and 50mg/kg/day for 6 months, followed by a 2-month posttreatment recovery period. A greater than dose-proportional increase in molindone exposure ([AUC]0‒24) was observed on Day 180 for both sexes. Statistically significant (P<0.01) increases in prolactin levels were observed in most treatment groups compared with controls at 0.5h postdose on Days 1 and 180. Prolactin levels returned to baseline levels during the recovery period. Microscopic changes attributable to hyperprolactinemia, including corpora lutea enlargement and interstitial cell atrophy in the ovaries, and atrophy of the uterus and vagina were observed on Day 180. These changes were reversed during the recovery period in the 5- and 15-mg/kg/day treatment groups. Mice receiving molindone at 50mg/kg/day also showed signs of reversal on histologic examination.
Supernus Pharmaceuticals Inc., Rockville, MD 20850, United States. Electronic address: gkrishna@supernus.com.
Gopala
G
Krishna
Advinus Therapeutics Ltd., Bengaluru, India. Electronic address: shivaputhrappa.g@advinus.com.
Shivaputhrappa
S
Ganiger
Advinus Therapeutics Ltd., Bengaluru, India. Electronic address: kamala.kannan@advinus.com.
Kamala
K
Kannan
Supernus Pharmaceuticals Inc., Rockville, MD 20850, United States. Electronic address: ggopalakrishnan@supernus.com.
Gopa
G
Gopalakrishnan
Supernus Pharmaceuticals Inc., Rockville, MD 20850, United States. Electronic address: saryu.goel@gmail.com.
Saryu
S
Goel
D000818:Animals; D001284:Atrophy; D015415:Biomarkers / Q000097:blood; D004195:Disease Models, Animal; D018492:Dopamine Antagonists; D005260:Female; D011905:Genes, ras; D006966:Hyperprolactinemia / Q000097:blood / Q000139:chemically induced / Q000235:genetics / Q000473:pathology*; D008297:Male; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008972:Molindone; D010053:Ovary / Q000473:pathology*; D011388:Prolactin / Q000097:blood; D013997:Time Factors; D014599:Uterus / Q000473:pathology*; D014621:Vagina / Q000473:pathology*
D015415:Biomarkers; D018492:Dopamine Antagonists; D011388:Prolactin; D008972:Molindone
Attention-deficit/hyperactivity disorder; Endocrine; Impulsive aggression; Molindone; Prolactin; Reproduction